Cargando…
T cells as the hoped-for savior for SARS-CoV-2 vaccination during CD20-depleting antibody therapy?: Commentary for: “Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.”
Autores principales: | Bsteh, Gabriel, Sellner, Johann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579751/ https://www.ncbi.nlm.nih.gov/pubmed/34773893 http://dx.doi.org/10.1016/j.ebiom.2021.103692 |
Ejemplares similares
-
Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy
por: Gadani, Sachin P., et al.
Publicado: (2021) -
Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy
por: Gadani, Sachin P., et al.
Publicado: (2021) -
SARS-CoV-2 vaccination in multiple sclerosis: A clearer picture for the time point during CD20 depleting therapy
por: Schulte, Eva C., et al.
Publicado: (2021) -
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?
por: Houot, Roch, et al.
Publicado: (2020) -
Humoral Immune Response after the Third SARS-CoV-2 mRNA Vaccination in CD20 Depleted People with Multiple Sclerosis
por: Achtnichts, Lutz, et al.
Publicado: (2021)